PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other tumors, including encapsulated genetically modified living cells. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. The company has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is based in Laguna Hills, California.
IPO Year:
Exchange: NASDAQ
Website: pharmacyte.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/8/2021 | Neutral | HC Wainwright & Co. |
HC Wainwright & Co. initiated coverage of PharmaCyte Biotech with a rating of Neutral
10-Q - PharmaCyte Biotech, Inc. (0001157075) (Filer)
10-K - PharmaCyte Biotech, Inc. (0001157075) (Filer)
NT 10-K - PharmaCyte Biotech, Inc. (0001157075) (Filer)
8-K - PharmaCyte Biotech, Inc. (0001157075) (Filer)
8-K - PharmaCyte Biotech, Inc. (0001157075) (Filer)
DEF 14A - PharmaCyte Biotech, Inc. (0001157075) (Filer)
ARS - PharmaCyte Biotech, Inc. (0001157075) (Filer)
10-Q - PharmaCyte Biotech, Inc. (0001157075) (Filer)
10-Q - PharmaCyte Biotech, Inc. (0001157075) (Filer)
8-K - PharmaCyte Biotech, Inc. (0001157075) (Filer)
New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (NASDAQ:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company's first investment in externally developed technology, which it believes will provide significant additional shareholder value and serv
Expresses Disappointment in the Board's Failure to Articulate a Plan to Maximize Shareholder Value Amid Prolonged Product Development Efforts Despite the Company's Strong Cash Position Criticizes the Company's Dismal Efforts to Communicate with Shareholders Including its Failure to Hold Quarterly Conference Calls Questions the Board and Management's Alignment with Shareholders Given Minimal Stock Ownership and Failure to Purchase Shares in the Open Market Calls on the Company to Actively Enlist Shareholder Participation in a Process to Refresh a Majority of the Directors on the Board with Highly Qualified Candidates to Fill Gaps in the Existing Leadership's Skillset and Bring Fresh Perspecti
Jonathan Schechter and Robert Weinstein Join Oblong's Board of Directors Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new directors to its board. Jonathan Schechter, Partner, The Special Equities Group, and Robert Weinstein, Chief Financial Officer, Synaptogenix, Inc. have joined Oblong's board of directors. In addition, Jim Lusk and Matthew Blumberg have retired from the Oblong board. "We're delighted to welcome Jonathan and Robert to the Oblong board of directors," said Pete Holst, President and CEO. "Both individuals bring a wealth of knowledge in mergers and acquisitions, digital transfor
Company Appoints Five New Independent Directors to Reconstituted Board PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that PharmaCyte and Iroquois Master Fund Ltd. and its affiliates, the beneficial owners of approximately 6.7% of PharmaCyte's outstanding shares of common stock, have signed a Cooperation Agreement that includes naming two of Iroquois' director designees to PharmaCyte's reconstituted Board of Directors. Pursuant to the Agreement, Iroquois' director designees, Jonathan L. Schechter and Jo
PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced its preliminary unaudited financial results for fiscal year ended April 30, 2022. Cash Position PharmaCyte had $85.4 million in cash and cash equivalents as of April 30, 2022. Preliminary (Unaudited) 2022 Fiscal Year End Financial Results PharmaCyte expects to report operating expenses of approximately $4.4 million, compared to $3.6 million in the prior fiscal year. This increase is primarily due to expenses associated with PharmaCyte listing on Nasdaq an
Believes the Company's Recently Announced Initiatives are a Reactionary and Transparent Attempt to Placate Stockholders by Conveniently Implementing a Few of Iroquois' Long-Standing Recommendations Without Addressing the Real Underlying Issues at the Company Questions the Company's Failure to Publicly Disclose the Material Terms of Executive Compensation Arrangements Recently Entered Into and How Such Arrangements Will Align Incentives Between the Company's Leadership and its Stockholders Identifies the Dysfunctional Board, Whose Members Have Been Hand-Picked by and Are Beholden to the Company's Chairman, Chief Executive Officer, President and General Counsel, Kenneth L. Waggoner, and its Di
PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the appointment of Dr. Matthias Löhr to PharmaCyte's Board of Directors. PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, stated, "PharmaCyte is extremely pleased that Dr. Löhr has joined our Board of Directors. There is no one who could be more qualified. His life's work and passion are specifically in the areas of the treatments that PharmaCyte is developing. He has held dozens of trusted leadership roles in learned societies, cancer research centers, universities,
Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD") a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions. MyMD has announced positive data for a 40-patient Phase 2 clinical trial for its lead product, MYMD-1 in sarcopenia, and is moving its clinical program forward in consultation with the U.S. Food and Drug Administration (FD
Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it has secured $7 million in commitments in two private placement funding rounds led by a strategic investor, PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a clinical-stage biotechnology company developing cellular therapies for cancer and diabetes. An additional $7 million was raised from existing MyMD
New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (NASDAQ:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company's first investment in externally developed technology, which it believes will provide significant additional shareholder value and serv
- $6.85 million upfront investment provides $23 million total cash runway into second half 2025 - - Financing allows for focused commercial team to bring Femasys' infertility-related products to women in the U.S. - - Additional financing supports the advancement of Femasys' lead product candidate, FemBloc® for permanent birth control, to initial clinical data readout - ATLANTA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products,
Company prepares for comprehensive discussion with FDA to determine appropriate next steps for technology while evaluating additional opportunities PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review of amassed data, the Company is in the process of requesting a meeting with the U.S. Food and Drug Administration (FDA) for guidance on further development of the technology. The meeting is expected to occur during the first quarter of 2024. In the meantime, the Company is reviewing multiple potential opportunities that i
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") today announces the final results of its previously announced tender offer to acquire up to 7,750,000 million shares of the Company's common stock, par value $0.001 per share, at a price of $3.25 per share in cash, less any applicable withholding taxes and without interest. The tender offer expired one minute after 11:59 p.m. on June 9, 2023, and was funded entirely through the Company's cash on hand. PharmaCyte CEO Josh Silverman commented, "Having completed the tender offer, we believe we are in a stronger position to optimize shareholder value. Our significant cash position of approximately $74 million following the
Jonathan Schechter and Robert Weinstein Join Oblong's Board of Directors Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new directors to its board. Jonathan Schechter, Partner, The Special Equities Group, and Robert Weinstein, Chief Financial Officer, Synaptogenix, Inc. have joined Oblong's board of directors. In addition, Jim Lusk and Matthew Blumberg have retired from the Oblong board. "We're delighted to welcome Jonathan and Robert to the Oblong board of directors," said Pete Holst, President and CEO. "Both individuals bring a wealth of knowledge in mergers and acquisitions, digital transfor
Concurrently, the Company Announces $35 Million Financing of Convertible Preferred Stock at $4.00 per Share PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicable withholding taxes and without interest. The Company also announces that it has completed a private placement financing of convertible redeemable preferred stock and warrants from existing investors, raising gross proceeds of approximately $35 million in a private placement financing of convertible redeemable preferred stock and warrants from existing investors. Tender Offer The Company intends to commence th
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box® for potential development of cellular therapies for cancer, diabetes and malignant ascites, announced today that its Board of Directors has authorized a second share repurchase program to repurchase up to $10 million of PharmaCyte's outstanding common stock. This second share repurchase authorization is effective immediately for a two-year period. PharmaCyte expects to fund the program with its available cash. The Company enacted a similar program in June 2022. PharmaCyte's CEO Josh Silverman commented, "Based
LAS VEGAS, Oct. 07, 2022 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box for potential development of cellular therapies for cancer, diabetes and malignant ascites, announces today that its Board of Directors has empowered its Business Review Committee to evaluate opportunities to realize optimal shareholder value. In addition, CEO Kenneth L. Waggoner has stepped down from the position as CEO effective October 6, 2022. The Board has since appointed Joshua N. Silverman, a member of the Board, as interim CEO. Mr. Silverman commented, "On
SC 13G/A - PharmaCyte Biotech, Inc. (0001157075) (Subject)
SC 13G - PharmaCyte Biotech, Inc. (0001157075) (Subject)
SC 13G/A - PharmaCyte Biotech, Inc. (0001157075) (Subject)
SC 13D/A - PharmaCyte Biotech, Inc. (0001157075) (Subject)
SC 13G - PharmaCyte Biotech, Inc. (0001157075) (Subject)
SC 13D/A - PharmaCyte Biotech, Inc. (0001157075) (Subject)
SC 13G/A - PharmaCyte Biotech, Inc. (0001157075) (Subject)
SC 13G/A - PharmaCyte Biotech, Inc. (0001157075) (Subject)
SC 13G/A - PharmaCyte Biotech, Inc. (0001157075) (Subject)
SC 13G - PharmaCyte Biotech, Inc. (0001157075) (Subject)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder valuePharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD") a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions. MyMD has announced positive data for a 40-patient Phase 2 clinical trial for its lead product, MYMD-1 in sarcopenia, and is moving its clinical program forward in consultation with the U.S. Food and Drug Administration (FDA).
New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder valuePharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (NASDAQ:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company's first investment in externally developed technology, which it believes will provide significant additional shareholder value and serve as
Company prepares for comprehensive discussion with FDA to determine appropriate next steps for technology while evaluating additional opportunitiesPharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review of amassed data, the Company is in the process of requesting a meeting with the U.S. Food and Drug Administration (FDA) for guidance on further development of the technology. The meeting is expected to occur during the first quarter of 2024. In the meantime, the Company is reviewing multiple potential opportunities that it be
On Monday, 369 companies set new 52-week lows. Intriguing Points From Today's 52-Week Lows: Danaher (NYSE:DHR) was the biggest company by market cap to set a new 52-week low. The smallest company in terms of market cap to set a new 52-week low was Ascent Solar Technologies (NASDAQ:ASTI). EBET (NASDAQ:EBET) saw the largest move of the companies, as shares plummetted 2955.38% to hit a new 52-week low. Fiserv (NYSE:FI) was the most promising stock of the group, with shares actually trading up 0.0% to bounce back after reaching its new 52-week low. Here are all the stocks that set new 52-week lows as of 10am on Monday: Danaher (NYSE:DHR) stock set a new 52-week low of $210.14 on M
On Tuesday, 386 stocks made new 52-week lows. Interesting Points From Today's 52-Week Lows: Diageo (NYSE:DEO) was the largest firm by market cap to set a new 52-week low. Neptune Wellness Solns (NASDAQ:NEPT) was the smallest company by market cap to set a new 52-week low. Vaccinex (NASDAQ:VCNX)'s stock came under the most pressure, trading down 1227.51% to reach a new 52-week low. Nouveau Monde Graphite (NYSE:NMG) shares were the most resilient of the group, as shares actually moved up 0.0% in response to hitting its 52-week low. Stocks dropping to new 52-week lows on Tuesday: Diageo (NYSE:DEO) stock broke to a new 52-week low of $151.08 on Tuesday. Shares of the company trade
Federal Funding Increases Fuel Research Progress and Help Improve Patient OutcomesLOS ANGELES, June 14, 2023 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading pancreatic cancer patient advocacy organization, today launched its Call on Congress Day campaign, part of its annual advocacy strategy to mobilize pancreatic cancer survivors, caregivers and supporters from around the United States to urge their members of Congress to increase the federal research investment for the world's deadliest cancer. This year, advocates are asking Congress to increase the investment in the dedicated Pancreatic Cancer Research Program at the Department of Defense (DOD) from $15 to $20 mi
Gainers Sunshine Biopharma (NASDAQ:SBFM) shares rose 45.1% to $0.77 during Thursday's pre-market session. The company's market cap stands at $17.3 million. Jaguar Health (NASDAQ:JAGX) stock rose 28.19% to $0.92. The company's market cap stands at $12.7 million. Ampio Pharmaceuticals (AMEX:AMPE) shares increased by 23.91% to $0.25. The company's market cap stands at $3.7 million. Tivic Health Systems (NASDAQ:TIVC) stock rose 18.32% to $0.2. The company's market cap stands at $5.7 million. PharmaCyte Biotech (NASDAQ:PMCB) stock increased by 15.69% to $3.17. The market value of their outstanding shares is at $55.2 million. Assure Hldgs (NASDAQ:IONM) stock rose 15.33% to $1.88. The company
Concurrently, the Company Announces $35 Million Financing of Convertible Preferred Stock at $4.00 per Share PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicable withholding taxes and without interest. The Company also announces that it has completed a private placement financing of convertible redeemable preferred stock and warrants from existing investors, raising gross proceeds of approximately $35 million in a private placement financing of convertible redeemable preferred stock and warrants from existing investors. Tender Offer The Company intends to commence the te